by Muhammad Raza Shah, Muhammad Imran, Shafi Ullah
Nanocarriers for Cancer Diagnosis and Targeted Chemotherapy reviews the principles and applications of nanocarriers for targeted drug delivery. Drug targeting involves active and passive strategies that exploit both the use of ligands for interactions and the physical and chemical properties of nanocarriers and micro-environments at target sites. Multidrug resistance and adverse side effects associated with anticancer drugs have attracted greater scientific attention and led formulation scientists to specifically target these drugs to target sites. Nanocarriers like liposomes, niosomes, gold nanorods, carbon nanotubes, and micelles are discussed for the delivery of drugs to specific disease sites. This is an important reference source for researchers in the biomedical and biomaterials fields who want to gain an understanding on how nanotechnology is used for earlier diagnoses and more effective cancer treatment. – Explores the fundamental principles of drug targeting through different nano-carriers, highlighting major applications – Shows how the use of nanocarriers is leading to quicker cancer diagnosis and more effective treatment – Discusses the major challenges of using nanocarriers for drug delivery and assesses how to overcome these barriers
Nanocarriers for Cancer Diagnosis and Targeted Chemotherapy (PDF)
10 $
Format: Publisher PDF
File size: 2191
Category: Medical Book
Be the first to review “Nanocarriers for Cancer Diagnosis and Targeted Chemotherapy (PDF)” Cancel reply
You must be logged in to post a review.

National Diagnostic Imaging Symposium 2015 (CME Videos)
Lippincott's Concise Illustrated Anatomy: Volume 3: Head & Neck
Lippincott's Concise Illustrated Anatomy: Volume 2: Thorax, Abdomen & Pelvis
Ocular Surface Disease: Cornea, Conjunctiva and Tear Film
Telemedicine and Electronic Medicine
Supporting Sucking Skills In Breastfeeding Infants 2nd
Epidemiology of Thyroid Disorders (EPUB)
Practical Manual of Histology (PDF) 


Reviews
There are no reviews yet.